Validea’s guru fundamental report for GSK PLC (ADR) (GSK) shows that it rates highest using the Acquirer’s Multiple Investor model by Tobias Carlisle. GSK is a large-cap growth stock in the Biotechnology & Drugs industry, with a 78% rating based on underlying fundamentals and stock valuation. The strategy looks for inexpensive stocks that could be potential takeover targets, with a score of 80% indicating interest and above 90% indicating strong interest. Tobias Carlisle is a deep value investing expert and author, known for his expertise in this area. Validea offers investment research services based on strategies of investment legends like Carlisle.

Read more at Nasdaq: GSK Quantitative Stock Analysis | Nasdaq